Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone
Sponsor: Insel Gruppe AG, University Hospital Bern
Summary
The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis * with tocilizumab, * while using less cortisone.
Official title: Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone: a Randomized, Multicenter, Adaptive, Blinded, Phase III Study
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
178
Start Date
2026-01
Completion Date
2032-08
Last Updated
2025-02-24
Healthy Volunteers
No
Conditions
Interventions
Prednisone
Participant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
Prednisone
Participant randomization to receive standard (26 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
Locations (1)
Department of Rheumatology and Immunology, Inselspital, University of Bern
Bern, Switzerland